|
|
|
|
Vol. 302, Issue 2, 787-794, August 2002
Department of Internal Medicine D (M.S., A.J., K.H.R., E.S.) and
Department of General Surgery (F.P.), University Clinics Münster,
University of Münster, Münster, Germany
Diadenosine polyphosphates (ApnA) (n = 3-6)
induced vasoconstrictions in isolated human mesenteric resistance
arteries (hMRAs) mounted in a microvessel myograph (rank order of
potency: Ap5A > Ap6A > Ap4A > Ap3A). The contractile
effects of ApnA in hMRA were similar to their effects in rat MRA
investigated previously. ATP, ADP, AMP, and adenosine had less
contractile potency than ApnA, suggesting that the observed effects
were not induced by the degradation products of ApnA. Ap4A- and
Ap5A-induced vasoconstriction was inhibited by
pyridoxalphosphate-6-azophenyl-2',4'-disulfonic acid (PPADS) (P2X
purinoceptor antagonist) but not by ADP3'5' (P2Y purinoceptor
antagonist). Thus, this purinergic vasoconstriction of hMRA seems to be
P2X but not P2Y purinoceptor-mediated. In precontracted hMRA all ApnA
caused vasorelaxations but (in contrast to rat MRA) the potencies of
the ApnA did not differ significantly from each other. The ApnA
degradation products had less vasorelaxing potency than ApnA,
demonstrating that the vasorelaxations can be ascribed to the ApnA
themselves. Ap5A-induced vasorelaxation of hMRA could neither be
inhibited with ADP3'5' nor with PPADS, which reveals a decisive
difference to the rat MRA where the inhibitory profile demonstrated the
importance of the P2Y purinoceptor for Ap5A-induced vasorelaxation.
However, Ap4A-induced vasorelaxation in hMRA could be inhibited by
ADP3'5'. These findings show that Ap4A-induced vasorelaxation in hMRA
is due to P2Y purinoceptor activation, that Ap5A evokes vasorelaxation
in hMRA via another mechanism than Ap4A, and that data derived from the
animal model cannot be simply transferred to human conditions.
This article has been cited by other articles:
![]() |
A. L. Garcia-Villalon, L. Monge, N. Fernandez, A. Salcedo, R. Narvaez-Sanchez, and G. Dieguez Coronary response to diadenosine pentaphosphate after ischaemia-reperfusion in the isolated rat heart Cardiovasc Res, February 1, 2009; 81(2): 336 - 343. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Vanholder, U. Baurmeister, P. Brunet, G. Cohen, G. Glorieux, J. Jankowski, and for the European Uremic Toxin Work Group A Bench to Bedside View of Uremic Toxins J. Am. Soc. Nephrol., May 1, 2008; 19(5): 863 - 870. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Steinmetz, G. Gabriels, T. V. Le, H.-J. Piechota, K. H. Rahn, and E. Schlatter Vasoactivity of diadenosine polyphosphates in human small renal resistance arteries Nephrol. Dial. Transplant., December 1, 2003; 18(12): 2496 - 2504. [Abstract] [Full Text] [PDF] |
||||